Korro Bio, Inc. — Form 10-Q

Korro Bio adopted a new 2026 Inducement Plan (100,000 shares reserved) for recruiting new employees under Nasdaq Rule 5635(c)(4), separate from its main equity plan. Simultaneously, it amended its non-employee director compensation policy effective April 8, 2026, setting annual board retainer at $40,000, committee retainers ranging from $5,000–$15,000, and equity grants (initial 0.128% of outstanding shares, annual 0.064%) with a $750,000 annual cap per director. On April 9, 2026, Korro engaged Rachel Meyers, Ph.D. as a consultant at $2,000/quarter for science advisory, with standard IP assignment, non-compete, and confidentiality terms.